Literature DB >> 3862580

Local therapy of rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma of children and adolescents.

G Prindull, H G Willert, G Notter.   

Abstract

Local control of the primary tumour is a fundamental requirement for clinical cure. Towards this aim, the primary tumour must be diagnosed early and identified histologically. The size, extension, and spread within the patient must be defined precisely. In planning effective local therapy, additional questions must be answered including resectability, mutilation, sensitivity to radio- and chemotherapy, anticipated morbidity from therapeutic measures, etc. For osteosarcoma there is no reasonable alternative to radical surgery. Because of the 20% local recurrence rate of Ewing's sarcoma following radiotherapy, radical surgical removal of the primary tumour should be attempted whenever possible. For rhabdomyosarcoma, particularly for its embryonal histology, non-radical removal of the primary sarcoma is still compatible with a cure, provided adequate radio- and chemotherapy is also administered. Primary irradiation is indicated in radiosensitive unresectable primary tumours and may convert these into an operable state. Chemotherapy is the domain of prevention and treatment of metastatic disease. It has, however, also a proved effect on primary tumours and, in several recent protocols, precedes local therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3862580     DOI: 10.1007/bf00451896

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  61 in total

1.  Rhabdomyosarcoma of head and neck in children. Combination treatment by surgery, irradiation, and chemotherapy.

Authors:  S S Donaldson; J R Castro; J R Wilbur; R H Jesse
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

2.  Radiatio herapy of malignant bone tumors.

Authors:  T L Phillips; G E Sheline
Journal:  Radiology       Date:  1969-06       Impact factor: 11.105

3.  Indications for surgical treatment of localized Ewing's sarcoma of bone.

Authors:  D J Pritchard
Journal:  Clin Orthop Relat Res       Date:  1980 Nov-Dec       Impact factor: 4.176

4.  The treatment of orbital rhabdomyosarcoma of children with primary radiation therapy.

Authors:  R H Sagerman; P Tretter; R M Ellsworth
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1972-01

5.  Rotation-plasty for childhood osteosarcoma of the distal part of the femur.

Authors:  R Kotz; M Salzer
Journal:  J Bone Joint Surg Am       Date:  1982-09       Impact factor: 5.284

6.  The prognostic significance of soft tissue extension in Ewing's sarcoma.

Authors:  C M Mendenhall; R B Marcus; W F Enneking; D S Springfield; T L Thar; R R Million
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

7.  Bladder and prostatic tumors in the intergroup Rhabdomyosarcoma study (IRS-I): results of therapy.

Authors:  D M Hays; R B Raney; W Lawrence; E H Soule; E A Gehan; M Tefft
Journal:  Cancer       Date:  1982-10-15       Impact factor: 6.860

8.  En bloc resections for osteogenic sarcoma.

Authors:  R C Marcove; G Rosen
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

9.  Childhood rhabdomyosarcomas of the head and neck.

Authors:  D E Schuller; T L Lawrence; W A Newton
Journal:  Arch Otolaryngol       Date:  1979-12

10.  Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma.

Authors:  A Razek; C A Perez; M Tefft; M Nesbit; T Vietti; E O Burgert; J Kissane; D J Pritchard; E A Gehan
Journal:  Cancer       Date:  1980-08-01       Impact factor: 6.860

View more
  2 in total

Review 1.  [Perioperative radiotherapy of bone and soft tissue tumors].

Authors:  H D Franke
Journal:  Langenbecks Arch Chir       Date:  1987

2.  Extraskeletal Ewing's Sarcoma of Neck in a Child- A Case Report.

Authors:  Mohammed-Humaam Ansari; Atishkumar-Balajirao Gujrathi; Vijayalaxmi Ambulgekar
Journal:  Iran J Otorhinolaryngol       Date:  2019-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.